150 related articles for article (PubMed ID: 2731314)
41. Uptake enhancement of platinum in the dog kidney by microencapsulation of cisplatin and local injection.
Hecquet B; Depadt G; Fournier C; Meynadier J
Anticancer Res; 1986; 6(1):65-9. PubMed ID: 3954334
[TBL] [Abstract][Full Text] [Related]
42. Assessment of the role of glutathione conjugation in the protection afforded by anethol dithiolthione against hexachloro-1,3-butadiene-induced nephrotoxicity.
Bouthillier L; Charbonneau M; Brodeur J
Toxicol Appl Pharmacol; 1996 Jul; 139(1):177-85. PubMed ID: 8685901
[TBL] [Abstract][Full Text] [Related]
43. Noninvasive estimation of bound and mobile platinum compounds in the kidney using a radiopharmacokinetic model.
Brechner RR; D'Argenio DZ; Dahalan R; Wolf W
J Pharm Sci; 1986 Sep; 75(9):873-7. PubMed ID: 3783454
[TBL] [Abstract][Full Text] [Related]
44. Resveratrol influences platinum pharmacokinetics: A novel mechanism in protection against cisplatin-induced nephrotoxicity.
Darwish MA; Abo-Youssef AM; Khalaf MM; Abo-Saif AA; Saleh IG; Abdelghany TM
Toxicol Lett; 2018 Jun; 290():73-82. PubMed ID: 29574132
[TBL] [Abstract][Full Text] [Related]
45. Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role?
Viale M; Vannozzi MO; Pastrone I; Mariggiò MA; Zicca A; Cadoni A; Cafaggi S; Tolino G; Lunardi G; Civalleri D; Lindup WE; Esposito M
J Pharmacol Exp Ther; 2000 Jun; 293(3):829-36. PubMed ID: 10869382
[TBL] [Abstract][Full Text] [Related]
46. Detection of platinum in the brain of mice treated with cisplatin and subjected to short-term hypoxia.
Minami T; Ichii M; Okazaki Y
J Pharm Pharmacol; 1996 May; 48(5):505-9. PubMed ID: 8799875
[TBL] [Abstract][Full Text] [Related]
47. Effect of cisplatin on calcium uptake by rat kidney cortical mitochondria.
Gemba M; Nakatani E; Teramoto M; Nakano S
Toxicol Lett; 1987 Oct; 38(3):291-7. PubMed ID: 3660432
[TBL] [Abstract][Full Text] [Related]
48. Organ-specific biotransformation of ormaplatin in the Fischer 344 rat.
Thompson DC; Vaisman A; Sakata MK; Wyrick SD; Holbrook DJ; Chaney SG
Cancer Chemother Pharmacol; 1995; 36(5):439-47. PubMed ID: 7634386
[TBL] [Abstract][Full Text] [Related]
49. Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews.
Eiseman JL; Beumer JH; Rigatti LH; Strychor S; Meyers K; Dienel S; Horn CC
Cancer Chemother Pharmacol; 2015 Jan; 75(1):143-52. PubMed ID: 25398697
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of nitric oxide synthase aggravates cisplatin-induced nephrotoxicity: effect of 2-amino-4-methylpyridine.
Saad SY; Najjar TA; Daba MH; Al-Rikabi AC
Chemotherapy; 2002; 48(6):309-15. PubMed ID: 12673106
[TBL] [Abstract][Full Text] [Related]
51. Changes in renal handling of platinum in cisplatinum-treated rats following induction of metabolic acidosis or alkalosis.
Bertolero F; Litterst CL
Res Commun Chem Pathol Pharmacol; 1982 May; 36(2):273-85. PubMed ID: 7201666
[TBL] [Abstract][Full Text] [Related]
52. Renal Medulla is More Sensitive to Cisplatin than Cortex Revealed by Untargeted Mass Spectrometry-Based Metabolomics in Rats.
Zhang P; Chen JQ; Huang WQ; Li W; Huang Y; Zhang ZJ; Xu FG
Sci Rep; 2017 Mar; 7():44804. PubMed ID: 28300186
[TBL] [Abstract][Full Text] [Related]
53. The mechanism of renal clearance of cisplatin (cis-dichlorodiammine platinum ii) and its modification by furosemide and probenecid.
Daley-Yates PT; McBrien DC
Biochem Pharmacol; 1982 Jul; 31(13):2243-6. PubMed ID: 6889863
[TBL] [Abstract][Full Text] [Related]
54. Vitamin E mitigates cisplatin-induced nephrotoxicity due to reversal of oxidative/nitrosative stress, suppression of inflammation and reduction of total renal platinum accumulation.
Darwish MA; Abo-Youssef AM; Khalaf MM; Abo-Saif AA; Saleh IG; Abdelghany TM
J Biochem Mol Toxicol; 2017 Jan; 31(1):1-9. PubMed ID: 27550472
[TBL] [Abstract][Full Text] [Related]
55. Effect of normal saline on cisplatin pharmacokinetics and antitumor activity in mice bearing P388 leukemia.
Fulco RA; Vannozzi M; Collecchi P; Merlo F; Parodi B; Civalleri D; Esposito M
Anticancer Res; 1990; 10(6):1603-10. PubMed ID: 2285232
[TBL] [Abstract][Full Text] [Related]
56. [Comparative study of the action of antineoplastic platinum compounds with varying nephrotoxic effects].
Bakhteeva VT; Fok EM; Lavrova EA
Vopr Med Khim; 1996; 42(4):301-6. PubMed ID: 9254514
[TBL] [Abstract][Full Text] [Related]
57. Association between increased atrial natriuretic peptide and reduced cisplatin nephrotoxicity in rats.
Ormond PM; Basinger MA; Jones MM; Hande KR
J Pharmacol Exp Ther; 1992 Jul; 262(1):246-51. PubMed ID: 1385629
[TBL] [Abstract][Full Text] [Related]
58. Toxicity of mercuric chloride to the developing rat kidney. III. Distribution and elimination of mercury during postnatal maturation.
Daston GP; Rehnberg BF; Hall LL; Kavlock RJ
Toxicol Appl Pharmacol; 1986 Aug; 85(1):39-48. PubMed ID: 3726886
[TBL] [Abstract][Full Text] [Related]
59. Long-term effects of acetazolamide and sodium chloride loading on cisplatin nephrotoxicity in the rat.
Heidemann HT; Hoffmann K; Inselmann G
Eur J Clin Invest; 1990 Apr; 20(2):214-8. PubMed ID: 2112487
[TBL] [Abstract][Full Text] [Related]
60. Renal metallothionein and platinum levels in diabetic and nondiabetic rats injected with cisplatin.
Cacini W; Singh Y
Proc Soc Exp Biol Med; 1991 Jul; 197(3):285-9. PubMed ID: 2068122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
